Early cancer detection is a lot more common these days than it was a decade ago. Exact Sciences (NASDAQ: EXAS) can't claim all the credit, but the non-invasive cancer tests that it markets play an important role. The company's cancer tests screened around 4 million people in 2021.
Despite a big audience for its products, shares of Exact Sciences fell about 40% last year, and they are still down about 56% from their peak in early 2021. Is this beaten-down growth stock a bargain now, or is it still too risky for most investors? Here's what you should know.
Exact Sciences made its mark with Cologuard, a non-invasive colon cancer screen. It's steadily funneled Cologuard revenue into innovative new modes of cancer detection that include a multi-cancer early detection (MCED) test for the broad public. Success in the highly coveted MCED arena could drive this stock through the roof, and Exact Sciences is making progress.
For further details see:
Down 40% in 2022, Can Exact Sciences Recover in 2023?